Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. World Health Organisation Global Report. 2016. Geneva, Switzerland. WHO/HTM/TB/201613E. Available at: http://www.who.int/tb/publications/global_report/en/ .
2. World Health Organisation. Anti-tuberculosis drug resistance in the World. Fourth global report. Report number WHO/HTM/TB/2008.39 http://whqlibdoc.who.int/hq/2008/WHO_HTM_TB_2008.394_eng.pdf .
3. Lew W, Pai M, Oxlade O, Martin D, Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med. 2008;149(2):123–34.
4. Menzies D, Benedetti A, Paydar A, Martin I, Royce S, Pai M, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med. 2009;6(9):e1000146.
5. Menzies D, Benedetti A, Paydar A, Royce S, Madhukar P, Burman W, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med. 2009;6(9):e1000150.